AngioDynamics (NASDAQ:ANGO) Stock Gets Price Target Reduction from HC Wainwright

Posted by Brenda Bartman on Oct 16th, 2026

AngioDynamics (NASDAQ:ANGO – Free Report) had its price objective cut by HC Wainwright from $19.00 to $18.00 in a report released on Tuesday, MarketBeat reports. They currently have a buy rating on the medical instruments supplier’s stock. HC Wainwright also issued estimates for AngioDynamics’ Q2 2027 earnings at ($0.11) EPS, Q3 2027 earnings at ($0.10) EPS, Q4 2027 earnings at ($0.02) EPS, FY2027 earnings at ($0.28) EPS, Q1 2028 earnings at ($0.09) EPS, Q2 2028 earnings at ($0.05) EPS, Q3 2028 earnings at ($0.02) EPS, Q4 2028 earnings at $0.02 EPS and FY2028 earnings at ($0.15) EPS.

Other equities research analysts also recently issued reports about the stock. Canaccord Genuity Group reiterated a “buy” rating and set a $20.00 target price on shares of AngioDynamics in a research report on Friday, October 9th. Weiss Ratings restated a “sell (d-)” rating on shares of AngioDynamics in a research report on Friday, July 17th. Wall Street Zen cut shares of AngioDynamics from a “buy” rating to a “hold” rating in a research report on Saturday, October 10th. Finally, Zacks Research raised shares of AngioDynamics from a “strong sell” rating to a “hold” rating in a research note on Monday, October 5th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $19.00.

Read Our Latest Report on AngioDynamics

AngioDynamics Trading Up 4.8%

AngioDynamics stock opened at $11.58 on Tuesday. The company has a market capitalization of $486.99 million, a PE ratio of -14.85 and a beta of 0.30. AngioDynamics has a 12 month low of $9.39 and a 12 month high of $16.29. The stock has a 50-day moving average price of $15.01 and a two-hundred day moving average price of $13.13.

AngioDynamics (NASDAQ:ANGO – Get Free Report) last announced its quarterly earnings results on Thursday, October 8th. The medical instruments supplier reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.07. The firm had revenue of $80.92 million for the quarter, compared to analyst estimates of $80.51 million. AngioDynamics had a negative return on equity of 4.49% and a negative net margin of 10.12%. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. As a group, analysts predict that AngioDynamics will post -0.26 earnings per share for the current fiscal year.

Insider Transactions at AngioDynamics

In other AngioDynamics news, SVP Warren Jr sold 23,370 shares of the firm’s stock in a transaction that occurred on Thursday, July 30th. The shares were sold at an average price of $14.72, for a total transaction of $344,006.40. Following the completion of the transaction, the senior vice president owned 64,745 shares in the company, valued at approximately $953,046.40. This trade represents a 26.52% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 6.00% of the company’s stock.

Institutional Investors Weigh In On AngioDynamics

Institutional investors have recently modified their holdings of the company. BlackRock Inc. bought a new position in AngioDynamics during the second quarter worth $49,480,000. Weber Capital Management LLC ADV bought a new stake in AngioDynamics during the second quarter valued at $17,649,392. Paradigm Capital Management Inc. NY bought a new stake in AngioDynamics during the second quarter valued at $8,732,000. Western Standard LLC bought a new stake in AngioDynamics during the second quarter valued at $5,037,000. Finally, Bank of America Corp DE boosted its position in AngioDynamics by 262.7% during the first quarter. Bank of America Corp DE now owns 503,640 shares of the medical instruments supplier’s stock valued at $5,726,000 after acquiring an additional 364,763 shares during the last quarter. 89.43% of the stock is owned by institutional investors.

Key AngioDynamics News

Here are the key news stories impacting AngioDynamics this week:

Positive Sentiment: HC Wainwright maintained a Buy rating and an $18 price target for AngioDynamics, implying substantial potential upside from the stock’s recent trading level. The firm projects improving results over time, including a return to quarterly profitability in Q4 2028. HC Wainwright Has Lowered Expectations for AngioDynamics Stock Price
Positive Sentiment: The company’s latest results provided some support: AngioDynamics reported a quarterly loss of $0.04 per share, better than the $0.11 loss analysts expected, while revenue of $80.92 million slightly exceeded forecasts.
Neutral Sentiment: HC Wainwright expects AngioDynamics’ losses to narrow from an estimated $0.28 per share in fiscal 2027 to $0.15 per share in fiscal 2028. The forecasts still imply the company will remain unprofitable over the near term.
Negative Sentiment: HC Wainwright reduced its fiscal 2027 EPS estimate to a $0.28 loss from a $0.27 loss, cut its Q2 2027 estimate to a $0.11 loss from $0.10, and lowered its Q3 2027 estimate to a $0.10 loss from $0.06. The firm also shifted its Q4 2027 forecast from a $0.01 profit to a $0.02 loss. These revisions indicate weaker near-term earnings expectations. Analyst Estimate Revisions
Negative Sentiment: A Seeking Alpha analysis said operational progress is evident but highlighted earnings volatility and persistent margin pressure. Those concerns, along with negative net margins and continued losses, may limit investor enthusiasm despite the long-term growth outlook. AngioDynamics: Progress Evident, But Volatility And Margin Concerns Persist

AngioDynamics Company Profile

(Get Free Report)

AngioDynamics, Inc is a medical device company that develops, manufactures and markets minimally invasive products for use in vascular disease, vascular access and oncology. Its technologies are designed to help physicians treat blood clots, restore blood flow, manage vascular access and ablate targeted tissue.

The company’s portfolio includes the Auryon platform for atherectomy, which uses laser technology to treat peripheral arterial disease; the AngioVac and AlphaVac systems for removing thrombus and other unwanted material from blood vessels; and BioSentry products used to seal biopsy tracts.